Diabetes Drug Discoveries: What the Future Holds : Market Research Report

Diabetes Drug Discoveries: What the Future Holds

Published by: Espicom Healthcare Intelligence

Published: Jan. 2, 2009 - 160 Pages

Foreword
Executive Summary
What is Diabetes?
A Global Problem: Where in the World?; The Economic Burden
Unhealthy Lifestyles; a Worrying Trend: Additional Health Risks for Young People
The Diabetes Therapy Market
Diabetes Management
Current Treatment Options: Initial Therapy; Metformin; Additional Therapies; Insulin; Sulphonylureas; Thiazolidinediones; Glinides; Alpha-glucosidase inhibitors; Amylin agonist; GLP-1 inhibitors; DPP-4 inhibitors
What’s in the Pipeline?: Further Development of Launched Products; Potential New Drugs
Competitor Ratio Analysis
Insulin & Insulin Analogues: Humulin (insulin human [rDNA origin]); Sales Forecast; Humalog (insulin lispro); Patents; Sales Forecast; Lantus (insulin glargine); Patents; Sales Forecast; Clinical Trials; INTENSIVE; GINGER; LACE; ELEONOR; OPAL; TULIP; LANMET; INSIGHT; AT.LANTUS; Apidra (insulin glulisine); Patents; Clinical Trials; GINGER; LACE; ELEONOR; OPAL; Levemir (insulin detemir); Patents; Clinical Trials; Levemir head-to-head with Lantus; PREDICTIVE; NovoRapid/NovoLog (insulin aspart); Patents; NovoMix/NovoLog Mix; Patents; Clinical Trials; PREFER
Recent Developments in Insulin Drug Delivery: Buccal Spray; Intranasal Insulin; Intranasal insulin may lower food intake in men and improve memory function in women; Oral Insulin; Insulin Suppository; Afresa (Technosphere Insulin System); Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Study 102 - comparable decreases in HbA1c levels; Study 030 - no adverse effect on lung function; Study 009; Generex Oral-lyn; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Generex Oral-lyn compared with insulin analogues; Phase II
Thiazolidinediones: Update on the use of TZDs in the consensus algorithm; Cardiovascular safety concerns; Long-term TZD use doubles women's fracture risk; Researchers map molecular regulation of adipocyte genetics; Avandia (rosiglitazone); Patents and Generic Competition; Sales Forecast; Safety Issues; Public Citizen petitions for Avandia ban; Diabetic macular oedema; Clinical Trials; APPROACH; ACCORD; RECORD; ADOPT; DREAM; RESULT; Rosiglitazone+atorvastatin; Rosiglitazone+fenofibrate; Actos (pioglitazone); Patents and Generic Competition; Sales Forecast; Safety Issues; Heart failure warning; Fracture risk; Clinical Trials; Research supports Actos’ Cardiovascular safety profile; Pioglitazone in NASH; CHICAGO; PROactive; COMPLEMENT; Balaglitazone; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Rivoglitazone; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class
GLP-1 Agonists: Byetta (exenatide); Patents; Sales Forecast; Safety Issues; Pancreatitis; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Exenatide versus sitagliptin; Exenatide versus biphasic insulin aspart; Exenatide as adjunctive therapy with thiazolidinedione; Long-acting release (LAR) formulation; Liraglutide; Sales Forecast; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical trial results; LEAD 6; LEAD 4; LEAD 3; Phase IIb; AVE0010; Sales Forecast; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Phase IIb; Phase IIa; Taspoglutide; Sales Forecast; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Phase II
DPP-4 inhibitors: Januvia (sitagliptin); Patents; Sales Forecast; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Januvia in combination therapy; Pooled analysis: safety and tolerability; Sitagliptin versus glipizide; Sitagliptin as monotherapy; Sitagliptin with metformin; Januvia with pioglitazone; Dose adjustment in patients with renal impairment; Galvus (vildagliptin); Sales Forecast; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; GALLANT; Pooled analysis of Phase III studies; Saxagliptin; Sales Forecast; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Saxagliptin+metformin; Treatment-na�ve Type II diabetes patients; Alogliptin; Sales Forecast; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Phase III; Early-phase data; Ondero (BI 1356); Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class
SGLT-2 Inhibitors: Dapagliflozin; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Phase II
Development Strategies for Type I Diabetes: Otelixizumab; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Phase II study; Teplizumab; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Phase I/II; DiaPep277; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Phase III interim analysis; Phase II; Diamyd; Competitor Ratio Analysis; Novelty/rationale for mechanism of action; Proof of concept/clinical data; Management/clinical expertise; Competition within the marketplace; Risks associated with drug development in therapeutic class; Clinical Trials; Phase II
Abbreviations
SOURCES
Espicom Sources
Others
List of Tables: Prevalence of Diabetes Worldwide by Region, 2000-2030 (000s); Prevalence of Diabetes in Top 25 Countries, 2000-2030 (000s); Summary of Treatments for Type II Diabetes; Launched Products in Development; Novel Drugs in Development; Competitor Ratio Analysis Summary; Leading Insulins and Insulin Analogues by Sales Value, 2006-2007 (US$ million); Humulin Sales, 2003-2008 (US$ million); Humalog Sales, 2003-2008 (US$ million); Humalog US Patents; Lantus Sales, 2003-2007 (EUR & US$ million); Lantus US Patents; Apidra US Patent; Levemir Sales, 2005-2008 (DKr & US$ million); Levemir US Patents; NovoRapid/NovoLog Sales, 2005-2008 (DKr & US$ million); NovoLog US Patents; NovoLog Mix US Patents; Thiazolidinedione Sales, 2006-2007 (US$ million); Avandia Sales, 2003-2007 (£ million and US$ million); Avandia US Patents; Actos Sales, 2004-2008 (¥ billion and US$ million); Actos US Patents; Byetta Sales, 2005-2008 (US$ million); Byetta US Patents; Januvia US Patents
List of Figures: Diabetes in the Top Ten Countries, 2000; Diabetes in the Top Ten Countries, 2030; UK Diabetes Therapy Market, 2007 (%); Novel Drugs in Clinical Development; Humulin Sales, 2003A-2013E (US$ million); Humalog Sales, 2003A-2013E (US$ million); Lantus Sales, 2003A-2013E (US$ million); Avandia Product Family Sales, 2003A-2013E (US$ million); Actos Sales, 2003A-2013E (US$ million); Byetta Sales, 2005A-2013E (US$ million); Liraglutide Sales, 2009E-2013E (US$ million); AVE0010 Sales 2011E-2015E (US$ million; Taspoglutide Sales 2011E-2015E (US$ million; Januvia/Janumet Sales, 2006A-2013 (US$ million); Galvus Sales, 2008A-2013E (US$ million); Saxagliptin Sales, 2009E-2013E (US$ million); Alogliptin Sales, 2009E-2013E (US$ million)

Abstract

This strategic report from Espicom puts the spotlight on current and future drugs that will be used in the treatment of Type I and Type II diabetes, providing industry and investors with a comprehensive overview of the market in the medium term.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Diabetes Drug Discoveries: What the Future Holds

Table of Contents

Abstract